Publication

Enhanced Absorption and Safety of MuscleBlaze CreAMP™: A Comparative Analysis With Regular Micronized Creatine Monohydrate in Healthy Male Adults

Learn how CreAMP shows higher bioavailability, longer half‑life, and lower clearance than standard creatine, analysed…

CertaraApril 1, 2025

Publication

The effect of high-fat diet on the pharmacokinetics of ondansetron hydrochloride tablets in healthy Chinese subjects

Find out how high‑fat meals significantly reduce ondansetron exposure, falling outside bioequivalence bounds, analysed using…

CertaraMarch 21, 2025

Publication

Effect of Food on the Pharmacokinetic Characteristics of a Single Oral Dose of D-1553, a Selective Inhibitor of KRASG12C, in Healthy Chinese Subjects`

Explore how high‑fat meals cause only modest PK changes in D‑1553, supporting administration without regard…

CertaraMarch 18, 2025

Publication

Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population

Discover how higher voriconazole concentrations and CYP2C19 variants predict thrombocytopenia and cholestasis in children, modelled…

CertaraFebruary 25, 2025

Publication

Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment

See how weight‑based multidose dalbavancin regimens achieve prolonged target attainment, supported by PK‑PD modelling in…

CertaraFebruary 13, 2025

Video

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Today’s drug candidates are more complex than ever. But with development decisions on the line,…

CertaraFebruary 12, 2025

Publication

Population pharmacokinetics of levetiracetam in Chinese adult epilepsy patients with varying renal function

Learn how creatinine clearance drives levetiracetam clearance; PopPK modelling supports renal‑adjusted dosing using Phoenix NLME.

CertaraFebruary 10, 2025

Publication

Bioequivalence of Water-Soluble Progesterone Injection (GenSci070) in Healthy Chinese Postmenopausal Women Volunteers

Find out how GenSci070 shows bioequivalence and comparable safety to reference progesterone injection in a…

CertaraJanuary 30, 2025

Publication

Comparison of RT-qPCR With Branched DNA to Quantify a Lipid Nanoparticle-Encapsulated mRNA Therapeutic in Serum and Liver Tissue Samples From Nonclinical PK Studies

Explore how RT‑qPCR provides a viable alternative to bDNA for mRNA‑LNP PK analysis, with comparable…

CertaraJanuary 16, 2025

Publication

Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs.

Discover how ondansetron and granisetron increase unbound platinum exposure versus palonosetron, modelled using Phoenix NLME.

CertaraDecember 22, 2024

Certara Products – Phoenix

Enhanced Absorption and Safety of MuscleBlaze CreAMP™: A Comparative Analysis With Regular Micronized Creatine Monohydrate in Healthy Male Adults

The effect of high-fat diet on the pharmacokinetics of ondansetron hydrochloride tablets in healthy Chinese subjects

Effect of Food on the Pharmacokinetic Characteristics of a Single Oral Dose of D-1553, a Selective Inhibitor of KRASG12C, in Healthy Chinese Subjects`

Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population

Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Population pharmacokinetics of levetiracetam in Chinese adult epilepsy patients with varying renal function

Bioequivalence of Water-Soluble Progesterone Injection (GenSci070) in Healthy Chinese Postmenopausal Women Volunteers

Comparison of RT-qPCR With Branched DNA to Quantify a Lipid Nanoparticle-Encapsulated mRNA Therapeutic in Serum and Liver Tissue Samples From Nonclinical PK Studies

Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs.

Newsletter sign up

Quick links

Solutions

Contact